Fig. 6: PCLX-001 selectively kills hematological cancer cells relative to benign lymphocytes in comparison to dasatinib and ibrutinib. | Nature Communications

Fig. 6: PCLX-001 selectively kills hematological cancer cells relative to benign lymphocytes in comparison to dasatinib and ibrutinib.

From: Targeting N-myristoylation for therapy of B-cell lymphomas

Fig. 6: PCLX-001 selectively kills hematological cancer cells relative to benign lymphocytes in comparison to dasatinib and ibrutinib.The alternative text for this image may have been generated using AI.

Cell viability curves of BL2 (solid lines) and IM9 cells (dotted lines) treated for 48 h (a) or 96 h (b) with 0.001–5 µM dasatinib, ibrutinib, or PCLX-001(2way Anova, Tukey’s multiple comparisons test, P < 0.0001) . Normalized cell viability of immortalized lymphocyte (IM9, VDS), BL (BL2, Ramos, BJAB), and DLBCL (DOHH2, WSU-DLCL2, SU-DHL-10) cell lines treated with 0.1 µM or 1.0 μM of dasatinib, ibrutinib or PCLX-001 for 48 h (c) and 96 h (d). Cell viability for all experiments was measured using Calcein assay and is an average of three independent experiments. (Ordinary one-way Anova, Dunnett’s multiple comparisons test) Errors bars depict s.e.m. Source data are provided as a Source Data file.

Back to article page